Distribution fate and mechanism of immune modulation following mucosal delivery of plasmid DNA encoding IL-10.

DNA vaccination has been widely studied in several models of vaccination and in the treatment of inflammatory diseases, even though the mechanism involved is still unclear. This report demonstrates that mucosal administration of plasmid DNA leads to rapid and widespread distribution around the body. Dissemination likely occurred via the bloodstream because plasmid DNA was present in blood plasma. The plasmid DNA was also detectable in several tissues including draining lymph nodes, spleen, liver, bone marrow, and even the dermis of ear pinnae. Except for the site of administration, plasmid DNA was no longer detectable in tissues after 3 wk postadministration. RNA and protein expression was also found in the tissues and bloodstream. Animals previously primed by HSV infection and subsequently given IL-10 DNA via the nasal mucosa, showed diminished Ag-induced delayed type hypersensitivity reactions for up to 5 wk posttreatment. The mechanism of modulation involved diminished the Ag-specific proliferation and production of Th1 cytokines. The Ag-specific silencing effects persisted beyond the duration of detectable plasmid encoded protein and was maintained upon adoptive transfer of T cells into a plasmid-free environment. The silenced T cells were not a source of IL-10, and their anergic state was reversible by exposure to Ag in the presence of exogenous IL-2.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  B. Rouse,et al.  Immune modulation by IL-10 gene transfer via viral vector and plasmid DNA: implication for gene therapy. , 1999, Cellular immunology.

[3]  B. Stockinger,et al.  DNA Vaccination:  Transfection and Activation of Dendritic Cells as Key Events for Immunity , 1999, The Journal of experimental medicine.

[4]  S. Parker,et al.  Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. , 1999, Journal of immunology.

[5]  S. Hoffman,et al.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. , 1998, Science.

[6]  R. Germain,et al.  Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization , 1998, The Journal of experimental medicine.

[7]  B. Rouse,et al.  Immunomodulation by mucosal gene transfer using TGF-beta DNA. , 1998, The Journal of clinical investigation.

[8]  B. Rouse,et al.  Modulation of Viral Immunoinflammatory Responses with Cytokine DNA Administered by Different Routes , 1998, Journal of Virology.

[9]  D. Weiner,et al.  Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. , 1998, Journal of immunology.

[10]  Anita B. Roberts,et al.  REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .

[11]  T. Tumpey,et al.  Chemokine synthesis in the HSV‐1‐infected cornea and its suppression by interleukin‐10 , 1998, Journal of leukocyte biology.

[12]  A. Rosenberg,et al.  Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory. , 1998, Journal of immunology.

[13]  R. Steinman,et al.  Antigen Presentation by Dendritic Cells after Immunization with DNA Encoding a Major Histocompatibility Complex Class II–restricted Viral Epitope , 1997, The Journal of experimental medicine.

[14]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[15]  B. Rouse,et al.  Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10. , 1997, Journal of immunology.

[16]  A. Iwasaki,et al.  Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. , 1997, Journal of immunology.

[17]  B. Rouse,et al.  Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization , 1997, Journal of virology.

[18]  J. T. Macgregor,et al.  Determination of tissue distribution of an intramuscular plasmid vaccine using PCR and in situ DNA hybridization. , 1996, Human gene therapy.

[19]  Simon C Watkins,et al.  DNA–based immunization by in vivo transfection of dendritic cells , 1996, Nature Medicine.

[20]  J. D. de Vries,et al.  Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells , 1996, The Journal of experimental medicine.

[21]  P. Godowski,et al.  Pharmacokinetics, tissue distribution, and expression efficiency of plasmid [33P]DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach. , 1996, Journal of pharmaceutical sciences.

[22]  B. Rouse,et al.  Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse-models , 1995, Journal of virology.

[23]  M. Hashida,et al.  Physicochemical and pharmacokinetic characteristics of plasmid DNA/cationic liposome complexes. , 1995, Journal of pharmaceutical sciences.

[24]  V. Godfrey,et al.  Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. , 1995, Journal of immunology.

[25]  B. Rouse,et al.  Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes. , 1995, Journal of immunology.

[26]  B. Rouse,et al.  T cell cytokine mRNA expression during the course of the immunopathologic ocular disease herpetic stromal keratitis. , 1995, Journal of immunology.

[27]  S. Parker,et al.  Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. , 1995, Human gene therapy.

[28]  B. Rouse,et al.  Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses. , 1995, International immunology.

[29]  Z. Xiang,et al.  Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. , 1995, Immunity.

[30]  T. Tumpey,et al.  Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1. , 1994, Journal of immunology.

[31]  Scott F. Smith,et al.  Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. , 1994, Science.

[32]  B. Rouse,et al.  Limitations and modifications of quantitative polymerase chain reaction. Application to measurement of multiple mRNAs present in small amounts of sample RNA. , 1993, Journal of immunological methods.

[33]  G. Acsadi,et al.  Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. , 1992, Human molecular genetics.

[34]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[35]  M. Mannik,et al.  Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA. , 1984, Clinical and experimental immunology.

[36]  A. Nash,et al.  Pathogenesis of herpes simplex virus in congenitally athymic mice: the relative roles of cell-mediated and humoral immunity. , 1982, The Journal of general virology.

[37]  B. Wu,et al.  Inhibition of PM-2 DNA degradation by a human serum protein. , 1982, Cancer research.

[38]  S. Hoch,et al.  Purification and characterization of two major DNA-binding proteins in human serum. , 1977, The Journal of biological chemistry.

[39]  P. Subramaniam,et al.  Mechanism of Interleukin-10 Inhibition of T-Helper Cell Activation by Superantigen at the Level of the Cell Cycle , 1999 .

[40]  P. Subramaniam,et al.  Mechanism of interleukin-10 inhibition of T-helper cell activation by superantigen at the level of the cell cycle. , 1999, Blood.

[41]  J. Ulmer,et al.  DNA vaccines. , 1997, Pharmacology & therapeutics.